One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday.

The latest to do so is Google parent company Alphabet, which has established Isomorphic Labs, under DeepMind head Demis Hassabis, to take its shot at the promising new field.

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday.

Alphabet has spun off a new company called Isomorphic Labs which seeks to use artificial intelligence to discover new pharmaceutical drugs. The commercial venture will reportedly build off of ...

Isomorphic Labs, the Alphabet Inc.-owned company that uses artificial intelligence to discover drugs, has raised $600 million, the first time it’s taken in external funding.

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune, Isomorphic Labs president Colin ...

In July, the company published a paper describing AlphaFold2, open-sourced the code, and dropped a library of 350,000 protein structures with a promise to add 100 million more. This week, Alphabet ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Isomorphic Labs is the secretive AI life sciences startup spun out of Google DeepMind with the goal of solving all disease with AI-powered drug discovery.

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech hub of Cambridge.

Isomorphic Labs sets up U.S. presence, with an eye on clinical trials The Alphabet company, spun off from DeepMind, is hiring a new chief medical officer and adding an office in Cambridge ...